Form 8-K · Current Report · Filed 2026-01-28
Halozyme Therapeutics Updates 2026 Financial Guidance and Announces Surf Bio Acquisition
Halozyme Therapeutics, Inc. has updated its 2026 financial guidance, projecting total revenue between $1,710 million and $1,810 million, royalty revenue between $1,130 million and $1,170 million, and non-GAAP diluted EPS between $7.75 and $8.25. The company also announced the acquisition of Surf Bio, Inc. for up to $400 million, which will enhance its drug delivery portfolio with hyperconcentration technology. These updates reflect strong performance in 2025 and strategic investments for future growth.
- Filer
- Halozyme Therapeutics Inc. HALO · NASDAQ
- Filed
- Accession
- 0001159036-26-000011
- CIK
- 0001159036
- Signal
- High impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Reported Item
Market reaction
Close before filing
$70.22
Next session
+4.4%
Since filing
+57.0%
Latest close
$110.24
What happened, not what will happen — closing prices around the filing date.
About Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc. is a biopharmaceutical company that specializes in developing and commercializing treatments focused on enhanced subcutaneous drug delivery. The company's proprietary technology, ENHANZE, aims to improve the efficacy and convenience of existing therapies by facilitating faster drug absorption and reducing the need for intravenous administration. Halozyme partners with major pharmaceutical companies to integrate its technology with a variety of treatments, significantly impacting the oncology, immunology, and genetic disorder sectors. This collaboration model helps expand the reach of its technology across multiple therapeutic applications. Based in San Diego, California, Halozyme is noted for its innovative approach to drug delivery, contributing to the broader pharmaceutical industry's efforts to improve patient experiences and optimize medical outcomes. As a significant player in the biopharmaceutical landscape, Halozyme's advancements continue to drive interest and growth within the market, underscoring the vital role of drug delivery technology in modern medicine.
Never miss another HALO filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.